Volume 2

Volume Two: Market Dynamics

Healthcare logistics, a market valued at an estimated ~$140B in 2026 and expected to surpass $200B by 2030,² has long been one of the most demanding and high‑stakes environments across all supply chain verticals. What has changed is not the underlying criticality of healthcare supply chains but rather the convergence of structural pressures that are pushing logistics performance from a back‑office consideration to a strategic priority. Supply chain disruptions during COVID exposed fragilities across global pharma, MedTech and diagnostics networks, while ongoing geopolitical tensions and capacity volatility have further increased the cost and risk of moving regulated healthcare products across borders. At the same time, sustained pricing and margin pressure on manufacturers and providers has elevated supply chain optimization from an efficiency lever to a source of competitive advantage. Together, these forces have created an inflection point for healthcare logistics companies able to deliver resilience, transparency and cost discipline at scale.

Compared with other logistics verticals, such as consumer or industrials, the items being transported carry consequences that go far beyond financial loss (which can still be significant for some products). A delay in shipment or a temperature deviation can directly affect patient outcomes, clinical integrity and even survival rates.

Consequently, healthcare logistics operate under stringent Service Level Agreements (SLAs), which are only intensifying as healthcare providers consolidate into larger, more sophisticated organizations with centralized procurement, standardized operating models and heightened expectations for performance and transparency. Especially after the COVID pandemic, providers are less tolerant of delivery uncertainty, inventory disruption and service variability from their logistics partners and increasingly view logistics as integral to their clinical and financial performance.

Furthermore, specialized handling, including cold‑chain management and chain‑of‑custody control, are becoming more critical with growth in biologics, cell and gene therapies, radiopharmaceuticals and other products with greater logistical complexity (and per unit cost). For example, vaccines, cell and gene therapies and tissue samples must be maintained within narrow temperature ranges or, in the case of radiopharmaceuticals, delivered within specified time horizons. Even minor deviations can render a product unusable and create liability. The pharma sector is estimated to lose ~$35 billion annually due to temperature‑controlled logistics failures, and up to 50% of vaccines globally are discarded because of temperature faults.^{3 4} These losses underscore not only the operational risk embedded in healthcare logistics but also the growing economic incentive to deploy AI, sensor technology and predictive analytics to anticipate disruptions, prevent excursions and reduce waste.

The combination of rising operational complexity, external shocks and economic pressure is exposing inefficiencies across the healthcare logistics ecosystem, while advances in AI, sensors and data infrastructure are making it increasingly feasible to address them. This backdrop is unlocking opportunity for specialized, high‑reliability service providers and technology‑enabled platforms to capture share, deepen customer integration and, ultimately, create defensible niches at the intersection of logistics and healthcare.

AI disruption and opportunity

AI offers a rare opportunity to leapfrog into a new era of operational maturity for a market segment historically characterized by paper trails, manual interventions and opaque vendor relationships. Beyond efficiency gains, AI has the potential to transform the structure of healthcare logistics itself, redefining how products are sourced, monitored and delivered, and how logistics providers interact with manufacturers, distributors and providers. Early adopters are already demonstrating that the integration of AI into logistics management can yield measurable improvements in performance, resilience and profitability. For investors, this evolution marks a shift from logistics as an asset- and labor-intensive service to a data- and insight-driven platform play. For strategics, this is both a threat and an opportunity.

Below are several case studies bringing to life real-world application of AI in healthcare logistics.

Competitive dynamics and investments in healthcare logistics

The convergence of structural market changes and AI-enablement are driving rapid consolidation, strategic expansion and the emergence of technology-driven, high-value operators. M&A activity is accelerating as buyers compete to secure high-quality, specialized operators capable of delivering reliability, compliance and technology-enabled performance, which translates into predictable cash flow generation while supporting the build-out of end-to-end service capabilities.

Private equity driving consolidation

Private equity has increasingly targeted specialized pharma and healthcare logistics providers, recognizing the combination of recurring revenue, regulatory barriers to entry and attractive margin profiles. Sponsors are focusing on operators with deep domain expertise in temperature-controlled logistics, clinical trial services and time-critical transportation. The industry’s continued high level of fragmentation enhances its appeal to private equity, as investors can deploy proven buy-and-build strategies, with global 3PLs and larger funds well-positioned to scale and support these platforms. Recent transactions illustrate this trend:

• Quality Life Science / Bluejay Capital (2025)
• Denali Growth / Tobin Scientific (2025)
• Argosy / Western Peak Logistics (2024)
• AUCTUS Capital / Life Courier (2023)
• SYZ / SK Pharma (2022)
• Atlantic Street Capital / Linden Capital / BioTouch (2018 / 2022)
• Blackstone / Life Science Logistics (2021)
• Swiss Life Asset Managers / Infrareal GmbH (2021)
• NB Aurora / PHSE (2020)

These investments reflect a broader strategy of building scaled, compliance-oriented platforms capable of serving pharmaceutical manufacturers, laboratories, hospitals and MedTech providers with increasingly complex service requirements.

In parallel, healthcare-focused private equity funds are increasingly moving downstream into logistics to control product delivery, integrity and patient access within the value chains they already invest in. Examples include:

• Water Street / GlobalMed Logistix (2026)
• Water Street / MedSpeed (2024)
• Assured Healthcare Partners / Pharma Logistics (2024)
• Archimed / Bomi (2019)

This strategy reflects a recognition that logistics performance directly impacts clinical outcomes, regulatory risk and brand reputation. Controlling or influencing the logistics layer enhances value creation across broader healthcare portfolios.

Global strategics expanding healthcare logistics footprints

Large global integrators and strategics are aggressively expanding their healthcare verticals, viewing the sector as structurally higher margin and less exposed to the cyclical volatility of traditional freight markets. Healthcare volumes, driven by biologics, diagnostics and chronic disease demand, provide defensible growth relative to industrial and consumer logistics.

Notable examples include:

• DHL / SDS Rx (2025)
• Cencora / NextPharma Logistics (2025)
• Nippon Express / Simon Hegele (2025)
• UPS / Andlauer (2025)
• Yusen / Walden (2025)
• UPS / Frigo Trans + BPL (2025)
• DHL / CryoPDP (2025)
• UPS / MNX (2023)
• UPS / Bomi (2022)
• Geodis / Trans-o-Flex (2022)

These transactions demonstrate a strategic push to acquire specialized capabilities in cold chain, final mile healthcare delivery and regulatory compliance rather than building them organically over extended timelines.

Emergence of bootstrapped technology-driven operators

Alongside sponsor-backed consolidation, a new class of attractive, founder-led assets is emerging. These companies differentiate themselves through deep healthcare domain expertise, operational discipline, and increasingly, proprietary technology platforms that enable visibility, compliance, and AI-driven supply chain orchestration. Examples include:

• DeSpir Logistics
• Langham Logistics
• BioRelo
• Alom
• Yourway

Often built organically, these businesses combine strong customer relationships with institutional-quality operations, making them highly attractive acquisition or partnership targets.

[2] Supply Chain Brain
[3 & 4] Research and Markets Healthcare Logistics Market Report 2026
[5] Freight Waves
[6] DHL Group
[7] UPS Healthcare
[8] Kuehne + Nagel

Volume 1

A mapping of the healthcare logistics ecosystem

Healthcare logistics is not a single market but rather an interconnected set of market subsegments, with specialized operators managing the flow of products and information between manufacturers and providers. See Exhibit 1 & 2.

Upstream, pharmaceutical, medical device and diagnostics manufacturers produce a wide variety of products under tightly regulated quality systems and a distributed global manufacturing footprint. Their labeling, serialization, temperature and service-level requirements cascade downstream, shaping the operational burden for all logistics partners.

Large broadline logistics providers, such as UPS, Fedex and DHL, play a critical role in moving bulk and parcel volumes from manufacturing plants and distribution centers to distributors and providers. Their value proposition centers on balancing speed, cost and temperature integrity at scale, often leveraging global networks and standardized operating models.

Distributors–both broadline and specialty–aggregate supply, manage inventory, provide last-mile replenishment and provide a growing list of supply chain services to hospitals, labs and non-acute sites of care. They act as buffers during shortages and differentiate through fill rates, cold-chain reliability and integration into provider procurement and track-and-trace systems. In addition, distributors have increasingly begun to sell their own self-manufactured or private label products, especially in medical devices. Distributors may work with repackagers, like Safecor, who take devices / medicines from manufacturers and repackage them to meet customer needs (e.g., unit dose prescriptions)

A growing layer of cold-chain specialists support temperature-sensitive therapies through validated packaging, cryogenic handling, sensors and real-time condition monitoring. As biologics, cell and gene therapies and personalized medicine expand, these capabilities move from premium add-ons to mission-critical infrastructure.

On the reverse‑flow side of the ecosystem, device reprocessors collect eligible single‑use devices, reprocess and / or repair them to approved standards and return them to use, reducing waste and total cost of care. Their operating models depend on reliable reverse logistics, documented chain of custody and consistent provider adherence to segregation and collection protocols.

Healthcare‑specialized 3PLs and couriers focus on orchestration rather than scale, managing warehousing, cross‑dock operations and temperature‑controlled last‑mile delivery, including STAT, OR‑direct and specimen movements. These providers win business based on SOP discipline, validated equipment, auditable chain of custody and time‑definite performance for clinically critical moves.

A distinct but closely related role is played by freight forwarders, particularly for international product flows. These players coordinate cross‑border transportation across air, ocean and ground, managing carrier selection, customs clearance, trade compliance and handoffs across jurisdictions. In healthcare, forwarders differentiate through validated lane management, temperature‑controlled air freight capabilities, regulatory expertise and the ability to dynamically reroute shipments during disruptions. These capabilities have become increasingly valuable amid geopolitical volatility and capacity constraints.

Finally, a set of reverse logistics and waste management providers handle returns, recalls, refurbishment and compliant destruction of regulated or hazardous waste. These services create value by accelerating credit and replacement cycles, minimizing write‑offs and maintaining rigorous regulatory documentation, capabilities that providers prioritize for risk control and audit readiness.

Overlaying the physical logistics network is a growing layer of software and data platforms that support planning, visibility and execution across the healthcare supply chain. Technology‑enabled players such as Altana, Flexport and other logistics software providers aggregate data across shippers, carriers and geographies to improve end‑to‑end visibility and predict disruptions. In healthcare‑specific applications, these platforms are increasingly tailored to regulated workflows, incorporating serialization data, temperature and condition monitoring and compliance documentation. Their asset‑light, data‑centric models offer scalable growth potential and the opportunity to become system‑of‑record or system‑of‑insight layers across a fragmented logistics ecosystem.

Overlaying the physical network is an increasingly important digital layer: logistics software, data visibility platforms and AI-enabled orchestration tools. These asset-light players aggregate data across shippers and carriers, predict disruptions and enable proactive intervention. As fragmentation persists across the ecosystem, these platforms are well-positioned to become system-of-record or system-of-insight layers.

The result is a fragmented but high-barrier ecosystem where specialization, compliance credibility and data integration drive competitive advantage.

[1] https://www.weforum.org/stories/2024/08/healthcare-costs-digital-tech